CRNX vs ROKU
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. ROKU: Roku operates a leading TV streaming platform that monetizes user engagement through digital advertising and subscription services while providing hardware to expand its household reach.
Side-by-side fundamentals
| Metric | CRNX | ROKU | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $83.92 | $150.07 | |
| Market cap as of 2026-08-08 | $8.8B | $22.7B | |
| P/E as of 2026-08-08 | n/a | 112.48 | |
| PEG as of 2026-08-08 | -0.73 | 1.84 | CRNX lower |
| Net margin as of 2026-08-08 | -1189.9% | +4.1% | ROKU higher |
| Gross margin as of 2026-08-08 | +86.0% | +44.2% | CRNX higher |
| Operating margin as of 2026-08-08 | -1302.5% | +2.1% | ROKU higher |
| ROE as of 2026-08-08 | -44.2% | +7.6% | ROKU higher |
| ROA as of 2026-08-08 | -39.8% | +4.6% | ROKU higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +16.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.9% | |
| Beta as of 2026-08-08 | 0.02 | 2.07 | |
| 1-year return as of 2026-08-06 close | +194.1% | +76.7% | CRNX higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.